On April 1, 2026, the FDA approved Eli Lilly’s Foundayo, the second oral GLP‑1 for weight loss – offering fewer administration restrictions and achieving one of the fastest new‑drug approvals in decades.
Meanwhile, Novo Nordisk is expanding access through a new multi‑month Wegovy subscription model and upcoming list‑price reductions. The table below shows subscription prices per month, along with annual savings compared with current standard self-pay pricing. Notably, Novo Nordisk has also announced that Wegovy’s list price is expected to decrease by about 50% beginning January 1, 2027.
Trends in this space include:
• Faster regulatory pathways
• Subscription and self‑pay access models
• Shifting list price vs. rebate dynamics
The conversation is moving quickly from availability to value, affordability, and sustainability.
For employers, and plan sponsors, the next 12-24 months will be critical in shaping long‑term GLP‑1 strategy, at ProAct, we help you manage GLP‑1 therapies today – while also building a long‑term strategy that accounts for innovation, cost trends, and responsible utilization.
